NCT03836079

Brief Summary

Safety and performance evaluation of the preCARDIA System for patients with ADHF.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2019

Longer than P75 for not_applicable

Geographic Reach
1 country

17 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 7, 2019

Completed
4 days until next milestone

First Posted

Study publicly available on registry

February 11, 2019

Completed
6 months until next milestone

Study Start

First participant enrolled

July 31, 2019

Completed
5.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 18, 2025

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 18, 2025

Completed
Last Updated

September 30, 2025

Status Verified

September 1, 2025

Enrollment Period

5.6 years

First QC Date

February 7, 2019

Last Update Submit

September 29, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • Freedom from Major Adverse Events through 90 days post-discharge.

    MAE is defined as death, myocardial infarction, major thromboembolic event, vascular damage requiring surgical intervention, hemorrhagic stroke or prolongation of heart failure- related hospitalization attributable to the preCARDIA device or procedure.

    90 days post-discharge

Study Arms (1)

ADHF Patients

EXPERIMENTAL

Treatment with preCARDIA System

Device: preCARDIA system

Interventions

Intermittent occlusion of the SVC

ADHF Patients

Eligibility Criteria

Age18 Years - 85 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • NYHA Class III-IV heart failure
  • Subjects with inadequate diuresis
  • Stage C-D systolic heart failure

You may not qualify if:

  • Active myocardial ischemia or acute coronary syndrome (ACS)
  • Severe aortic or mitral valve insufficiency
  • Severe peripheral vascular disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (17)

Colorado Heart & Vascular

Lakewood, Colorado, 80226, United States

Location

Medstar Washington Hospital Center

Washington D.C., District of Columbia, 20010, United States

Location

Tampa General Hospital

Tampa, Florida, 33606, United States

Location

Northwestern

Chicago, Illinois, 60611, United States

Location

University of Chicago

Chicago, Illinois, 60637, United States

Location

Kansas University Medical Center

Kansas City, Kansas, 66160, United States

Location

Tufts Medical Center

Boston, Massachusetts, 02111, United States

Location

Minneapolis Heart Institute Foundation

Minneapolis, Minnesota, 55407, United States

Location

CentraCare Heart & Vascular Center

Saint Cloud, Minnesota, 56303, United States

Location

OhioHealth

Columbus, Ohio, 43214, United States

Location

Providence Health & Services

Portland, Oregon, 97225, United States

Location

Allegheny General Hospital

Pittsburgh, Pennsylvania, 15212, United States

Location

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

Location

Baylor College of Medicine

Houston, Texas, 77030, United States

Location

Houston Methodist

Houston, Texas, 77030, United States

Location

Baylor, Scott & White Medical Center - Temple

Temple, Texas, 76508, United States

Location

Inova Health System

Falls Church, Virginia, 22042, United States

Location

Related Publications (1)

  • Kapur NK, Kiernan MS, Gorgoshvili I, Yousefzai R, Vorovich EE, Tedford RJ, Sauer AJ, Abraham J, Resor CD, Kimmelstiel CD, Benzuly KH, Steinberg DH, Messer J, Burkhoff D, Karas RH. Intermittent Occlusion of the Superior Vena Cava to Improve Hemodynamics in Patients With Acutely Decompensated Heart Failure: The VENUS-HF Early Feasibility Study. Circ Heart Fail. 2022 Feb;15(2):e008934. doi: 10.1161/CIRCHEARTFAILURE.121.008934. Epub 2022 Jan 10.

MeSH Terms

Conditions

Heart FailureHeart Diseases

Condition Hierarchy (Ancestors)

Cardiovascular Diseases

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DEVICE FEASIBILITY
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

February 7, 2019

First Posted

February 11, 2019

Study Start

July 31, 2019

Primary Completion

February 18, 2025

Study Completion

February 18, 2025

Last Updated

September 30, 2025

Record last verified: 2025-09

Data Sharing

IPD Sharing
Will not share

Locations